Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

20/20 BioLabs Q3 revenue slips to $0.38M; Vermont firefighter cancer screening contract signed

The US diagnostics company reported a third-quarter net loss of $1.38M, while a two-year Vermont screening deal is expected to add revenue in the fourth quarter.

16 Nov 2026 · 20/20 Biolabs, Inc. AIDX · Company news

20/20 BioLabs reported results for the quarter ended 30 September 2026 in a release dated 16 November. Third-quarter revenue was $0.38M, down from $0.42M in the same period a year earlier, and the company recorded a net loss of $1.38M.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): 20/20 Biolabs, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →